ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February and August 2026, up from exactly one in the prior six-month window — a 1900% increase that makes antibody-drug conjugates the fastest-accelerating modality in biopharma deal-making this year. This isn't a gentle uptick; it's a step-change driven by convergent forces: Big Pharma's desperation to backfill LOE-exposed oncology portfolios, a maturing payload-linker technology base that's finally de-risking clinical translation, and a generation of biotechs that have learned to time their licensing leverage to perfection.

The Data — ADC Deal Activity, Period over Period

The base period — late August 2025 through late February 2026 — was anomalously quiet. A single recorded deal in six months doesn't reflect a dead modality; it reflects a market that was holding its breath. Several large-cap pharmas were in active diligence but hadn't yet pulled the trigger. The floodgates opened in Q1 2026 and haven't closed. The resulting 20-deal burst is the densest ADC licensing window since the post-Enhertu frenzy of 2023, and the deal structures look materially different this time.

What's Driving the Trend

Pipeline gaps are the primary accelerant. At least six top-20 pharma companies face oncology revenue cliffs between 2027 and 2030 as checkpoint inhibitor exclusivity erodes. ADCs represent the most clinically validated next-generation modality with a clear reimbursement pathway — payers understand them, KOLs prescribe them, and regulators have established a review template after 14 FDA-approved ADCs to date. For a BD team tasked with bringing in a Phase 2 asset that can reach the market by 2029, ADCs are the lowest-risk bet on the board.

The technology has matured past the tipping point. Third-generation linker chemistries, site-specific conjugation, and novel topoisomerase I inhibitor payloads have widened the therapeutic index enough that clinical attrition rates for ADCs have dropped measurably. DealForma data shows ADC Phase 2 success rates climbing from roughly 28% in 2020–2022 to an estimated 39% in 2024–2026 cohorts. That de-risking shows up directly in deal economics: licensees are willing to pay larger upfronts because the probability-adjusted NPV math has shifted in the modality's favor.

Capital availability has returned to the space. Biotech IPO windows reopened in late 2025, and crossover rounds for clinical-stage ADC companies have been oversubscribed. That gives licensors alternatives to licensing — they can fund programs internally — which creates urgency on the buy side. When your target has the cash to say no, you pay more and you move faster. This dynamic is visible in the upfront-to-TDV ratios we're seeing, which have compressed from roughly 8–10% in 2023 to 11–14% in 2026 ADC deals, reflecting seller leverage.

Notable Deals

GSK-Hansoh ($185M upfront / $1.7B TDV) is the marquee transaction. The $185M upfront — roughly 10.9% of total deal value — is at the lower end of ADC upfront ratios we've tracked on Deal Benchmarks this year, suggesting GSK negotiated favorable risk-sharing terms, likely tied to aggressive clinical milestones. This deal signals GSK's serious re-entry into oncology ADCs after a relatively quiet 2024–2025. Hansoh's differentiated payload platform gave GSK access to a clinical-stage asset without a competitive auction, which likely explains the discount to market upfront ratios.

Novartis-Myricx Bio ($1.5B + $1.1B TDV across two agreements) is the more strategically significant signal. Two deals announced on the same day, totaling $2.6B in aggregate deal value, indicate a platform-level bet rather than an asset pick. Novartis is building an ADC engine through in-licensing rather than M&A — a deliberate strategic choice that preserves optionality. The absence of disclosed upfronts suggests equity-based or option-structured deals, a format gaining traction with early-stage licensors who want to retain more upside.

Biocytogen-Whitehawk ($500M TDV) represents the emerging mid-market layer of ADC licensing activity in 2026. Whitehawk — a specialty-focused vehicle — is emblematic of a new buyer class: well-capitalized platforms that lack internal R&D but have commercial infrastructure for targeted oncology launches. These buyers are willing to pay full TDV but structure deals with lower (or zero) upfronts and heavier milestone loading. Expect this buyer archetype to account for 25–30% of ADC licensing volume by year-end.

What This Means for BD Teams Right Now

If you're a licensor with a differentiated ADC asset, this is the most favorable seller's market since 2023. Twenty deals in six months means your buyer universe is deep and competitive. Run a process — don't accept the first term sheet. Upfront-to-TDV ratios above 12% are achievable for Phase 2 assets in solid tumors with a differentiated target or payload. Use Solidus to benchmark your term sheet against the current cohort before you sign.

If you're buying, speed is now a competitive advantage, not a risk factor. The best ADC assets are clearing the market in 60–90 days from initial CDA to signed term sheet. Extended diligence timelines — the 6-month cycles that were standard in 2024 — are costing buyers deals. Teams that can compress diligence to 8 weeks and show up with a credible upfront number on the first call are winning. Consider pre-cleared term sheet frameworks for your priority targets.

Deal structures are shifting toward hybrid models. Pure milestone-heavy structures are losing favor with licensors who now have leverage. We're seeing more equity kickers, co-development options, and tiered royalty structures that give licensors asymmetric upside in blockbuster scenarios. If your standard template is a 2019-era milestone ladder, update it. Licensors' advisors are benchmarking every term against the Hansoh and Myricx deals in real time.

Target selection matters more than ever. The 20-deal surge includes assets across at least 12 distinct tumor targets. The market is not yet crowded enough that target overlap is compressing deal values, but by mid-2027 it will be. Buyers should focus on targets with limited competitive ADC programs — avoid the HER2 and Trop-2 pileups unless the differentiation story is airtight. Sellers on crowded targets should move now before the window narrows.

Benchmark your deal against current market rates. Whether you're structuring an upfront, negotiating milestones, or setting royalty tiers, the 2026 ADC deal cohort has reset the baseline. Use the Ambrosia calculator to see where your terms land relative to the 20 deals that have closed this cycle — and identify exactly where you're leaving value on the table.

FAQs

Is the 1900% increase in ADC deal activity sustainable through 2027?

The base period of 1 deal inflates the percentage, but the absolute volume of 20 deals in six months is significant by any historical standard. Based on the pipeline of ADC assets approaching clinical milestones and Big Pharma's stated oncology acquisition priorities, we project 30–35 ADC deals in the 12 months ending February 2027. The pace won't sustain a 1900% growth rate — that's mathematically improbable — but absolute deal volume will remain elevated as long as LOE-driven pipeline gaps persist and ADC clinical success rates hold above 35% in Phase 2.

How should biotech CFOs think about ADC licensing 2026 deal economics versus pursuing an IPO?

ADC licensing deal values have risen enough that the calculus has shifted for many clinical-stage companies. A $150–200M upfront in a $1.5B TDV deal delivers non-dilutive capital that would require a $600M+ IPO to match on a post-dilution basis. However, licensing locks in a ceiling on program value. For companies with Phase 2 data in hand and a differentiated mechanism, the optimal play may be a partial-rights deal — license ex-US rights while retaining US commercial rights — which preserves optionality. Check your specific scenario against comparable deal structures on Deal Benchmarks.

Which ADC payload classes are commanding the highest deal values in 2026?

Topoisomerase I inhibitor-based ADCs continue to dominate deal volume, accounting for roughly 55% of the 20 deals in the current window. However, the highest per-deal TDVs are clustering around novel payload classes — particularly immune-stimulating ADCs and dual-payload conjugates. The Myricx-Novartis deals, totaling $2.6B in TDV, reportedly involve a proprietary payload platform outside the standard DXd/MMAE/MMAF taxonomy. Buyers are paying a 20–30% premium for payload differentiation versus me-too topoisomerase I programs.